What is ProteoGenex?
ProteoGenex is a prominent provider of human biological specimens and associated clinical data, offering a comprehensive catalog that includes Fresh Frozen, Formalin-Fixed Paraffin-Embedded (FFPE), and Tissue Microarray (TMA) formats. The company's product line extends to blood products, RNA, DNA, and biofluids sourced from both healthy and diseased donors. ProteoGenex serves a diverse clientele within academic and industrial research settings, with a particular emphasis on custom collection services and stringent quality control measures. Their operations are guided by a commitment to ethical practices and continuous innovation, aiming to advance research and clinical applications in the life sciences.
How much funding has ProteoGenex raised?
ProteoGenex has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for ProteoGenex?
The substantial late-stage funding indicates ProteoGenex is poised for significant scaling and expansion. This strategic capital infusion is likely to fuel advancements in their specimen processing capabilities, broaden their service offerings, and potentially enhance their global reach. The company's focus on high-quality biological materials and clinical data positions it to capitalize on the growing demand for reliable research resources in drug discovery, diagnostics, and personalized medicine.
See full ProteoGenex company page
